Navigating the world of cell and gene therapy development and commercialisation

By Annabel Kartal-Allen | Published: 27-Sep-2024
Cell & Gene Therapy

Manufacturing Chemist’s Annabel Kartal-Allen (AKA) spoke to Adam Goldstein (AG), Senior Director of R&D Collaborations at Thermo Fisher Scientific, about the current trends in CGT manufacturing and how to optimise and commercialise the process

You need to be a subscriber to read this article.
Click here to find out more.

Initially discussing the latest trends in the biopharma industry, Adam notes that process analytical technology (PAT) has seen significant evolution in recent years and become an important component in terms of accelerating development timelines. PAT solutions enable the simple scaling of manufacturing processes to facilitate the production of biologics and cell and gene therapies (CGTs).

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Thermo Fisher Scientific
See more

You may also like

Cell & Gene Therapy

Thermo Fisher launches next-gen microarray analyser to accelerate pharmacogenomic research

Read more
The analyser combines four key genotyping processes into a single, integrated device, allowing researchers to cover the widest range of populations for genome-wide association studies

Trending Articles

  1. Avant Technologies and Austrianova launch joint venture Klothonova and its groundbreaking Klotho development programme Using Austrianova's cell-encapsulation technology, the duo aim to engineer a genetically modified cell line that overexpresses the 'longevity protein' Klotho, paving the way for innovative cell-based therapies to combat age-related diseases
  2. Bristol Myers Squibb strengthens and diversifies cell therapy portfolio with acquisition of Orbital Therapeutics Bristol Myers Squibb will acquire Orbital Therapeutics in a $1.5bn deal, adding next-generation RNA-based in vivo CAR T technology to its cell therapy pipeline and expanding treatment potential in autoimmune diseases
  3. Alithea Genomics launches extraction-free, RNA-seq for 3D drug screening and toxicology The streamlined, one-day workflow delivers full transcriptome coverage in a massively multiplexed manner, making the method ideal for large-scale mechanistic and toxicity studies in 3D models
  4. Thermo Fisher launches next-gen microarray analyser to accelerate pharmacogenomic research The analyser combines four key genotyping processes into a single, integrated device, allowing researchers to cover the widest range of populations for genome-wide association studies
  5. Syngene launches platform for rapid, enhanced protein production The CRDMO aims to optimise protein production, facilitating the rapid movement of recombinant proteins through preclinical and clinical development

You may also like

Cell & Gene Therapy

Thermo Fisher launches next-gen microarray analyser to accelerate pharmacogenomic research

The analyser combines four key genotyping processes into a single, integrated device, allowing researchers to cover the widest range of populations for genome-wide association studies
Manufacturing

Thermo Fisher teams up with Xcellbio to further cell and gene therapy research

The pair will focus on Treg and TIL research, with the intention of developing therapeutics for autoimmune and solid tumour diseases
Manufacturing

Thermo Fisher Scientific enhances biologics manufacturing sustainability with biobased solutions

The single use, plant-based film for bioprocessing containers can reduce the carbon footprint of biologics manufacturing by eliminating the need for plastic resin
Manufacturing

Multiply Labs and Thermo Fisher Scientific expand partnership to automate cell expansion and separation

Automating GMP-ready instruments using robotic technology helps reduce costs and accelerates timelines
Finance

Funding for commercialisation of Rexgenero cell therapy

TrakCel, a specialist software developer for cell and gene therapy supply chain tracking and orchestration, announced the consortium comprising itself, the Cell and Gene Therapy (CGT) Catapult, Rexgenero and Fisher Bioservices (part of Thermo Fisher Scientific) has secured funding of £1.4 million from Innovate UK
Research & Development

New pluripotent stem cell media eliminates need for daily feeding

Allows two full-day breaks without changes to set up or protocol
Manufacturing

Accellta grants feeder-free stem cell culture medium rights to Thermo Fisher

Stem cell company grants worldwide non-exclusive rights to Thermo Fisher to manufacture and distribute its proprietary cell culture medium and ancillary products and methods
Subscribe now